{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:24:21Z","timestamp":1793863461085,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.eururo.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:04:18Z","timestamp":1683853458000},"page":"229-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES"],"prefix":"10.1016","volume":"84","author":[{"given":"Andrew J.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnauld","family":"Villers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Alekseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell Z.","family":"Szmulewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Holzbeierlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gomez-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Rosbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Zohren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel P.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Gourgiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"El-Chaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.04.002_b0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrurol.2016.175","article-title":"Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations","volume":"14","author":"Tosoian","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2023.04.002_b0010","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.21037\/tau-20-1033","article-title":"Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review","volume":"10","author":"Mahjoub","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2023.04.002_b0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.prnil.2020.12.003","article-title":"Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer","volume":"9","author":"Preisser","year":"2021","journal-title":"Prostate Int"},{"key":"10.1016\/j.eururo.2023.04.002_b0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","article-title":"Impact of the site of metastases on survival in patients with metastatic prostate cancer","volume":"68","author":"Gandaglia","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.002_b0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0035","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.002_b0045","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3390\/cancers14082017","article-title":"Where do we stand in the management of oligometastatic prostate cancer? A comprehensive review","volume":"14","author":"Juan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2023.04.002_b0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.eururo.2023.04.002_b0055","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.04.002_b0060","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0065","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone in metastatic prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.04.002_b0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.04.002_b0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.04.002_b0080","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0085","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0090","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.04.002_b0095","doi-asserted-by":"crossref","first-page":"S1176","DOI":"10.1016\/j.annonc.2022.07.1517","article-title":"1385P transcriptome-based prognostic and predictive biomarker analysis of ENACT: a randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)","volume":"33","author":"Ross","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12894-022-00979-9","article-title":"Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan","volume":"22","author":"Leith","year":"2022","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2023.04.002_b0105","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","article-title":"Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States","volume":"206","author":"Ryan","year":"2021","journal-title":"J Urol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2023.04.002_b0110","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2021.39.15_suppl.5074","article-title":"Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings","volume":"39","author":"George","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2023.04.002_b0115","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1200\/JCO.2021.39.15_suppl.5072","article-title":"Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database","volume":"39","author":"Swami","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0120","unstructured":"Astellas Pharma US Inc., Pfizer Inc. XTANDI US Prescribing Information. 2021."},{"key":"10.1016\/j.eururo.2023.04.002_b0125","unstructured":"Astellas Pharma US Inc., Pfizer Inc. Xtandi summary of product characteristics. 2021."},{"key":"10.1016\/j.eururo.2023.04.002_b0130","unstructured":"Astellas Pharma Inc. Xtandi\u00ae (enzalutamide) package insert \u2013 updated Japanese indication. 2020."},{"key":"10.1016\/j.eururo.2023.04.002_b0135","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12998\/wjcc.v8.i1.54","article-title":"Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: a study of 1358 patients","volume":"8","author":"Cui","year":"2020","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.eururo.2023.04.002_b0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.37549\/ARO1243","article-title":"Management of oligometastatic prostate cancer","volume":"9","author":"Broughman","year":"2020","journal-title":"Appl Radiat Oncol"},{"key":"10.1016\/j.eururo.2023.04.002_b0150","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2023.04.002_b0155","doi-asserted-by":"crossref","first-page":"e046588","DOI":"10.1136\/bmjopen-2020-046588","article-title":"A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design","volume":"11","author":"Freedland","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2023.04.002_b0160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13014-021-01849-8","article-title":"Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer","volume":"16","author":"Rogowski","year":"2021","journal-title":"Radiat Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823027239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823027239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:46Z","timestamp":1759583626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823027239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0302283823027239"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.04.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}